Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Pharmacogenomics of Cisplatin-Induced Ototoxicity: Successes, Shortcomings, and Future Avenues of Research.

Drögemöller BI, Wright GEB, Lo C, Le T, Brooks B, Bhavsar AP, Rassekh SR, Ross CJD, Carleton BC.

Clin Pharmacol Ther. 2019 Aug;106(2):350-359. doi: 10.1002/cpt.1483. Epub 2019 Jun 12. Review.

PMID:
31012503
2.

Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis.

Kowalec K, Wright GEB, Drögemöller BI, Aminkeng F, Bhavsar AP, Kingwell E, Yoshida EM, Traboulsee A, Marrie RA, Kremenchutzky M, Campbell TL, Duquette P, Chalasani N, Wadelius M, Hallberg P, Xia Z, De Jager PL, Denny JC, Davis MF, Ross CJD, Tremlett H, Carleton BC.

Nat Genet. 2018 Aug;50(8):1081-1085. doi: 10.1038/s41588-018-0168-y. Epub 2018 Jul 16.

3.

An initial health economic evaluation of pharmacogenomic testing in patients treated for childhood cancer with anthracyclines.

Dionne F, Aminkeng F, Bhavsar AP, Groeneweg G, Smith A, Visscher H, Rassekh SR, Ross C, Carleton B.

Pediatr Blood Cancer. 2018 Mar;65(3). doi: 10.1002/pbc.26887. Epub 2017 Dec 22.

PMID:
29271558
4.

Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer.

Drögemöller BI, Monzon JG, Bhavsar AP, Borrie AE, Brooks B, Wright GEB, Liu G, Renouf DJ, Kollmannsberger CK, Bedard PL, Aminkeng F, Amstutz U, Hildebrand CA, Gunaretnam EP, Critchley C, Chen Z, Brunham LR, Hayden MR, Ross CJD, Gelmon KA, Carleton BC.

JAMA Oncol. 2017 Nov 1;3(11):1558-1562. doi: 10.1001/jamaoncol.2017.0502.

5.

Pharmacogenetic variants in TPMT alter cellular responses to cisplatin in inner ear cell lines.

Bhavsar AP, Gunaretnam EP, Li Y, Hasbullah JS, Carleton BC, Ross CJ.

PLoS One. 2017 Apr 13;12(4):e0175711. doi: 10.1371/journal.pone.0175711. eCollection 2017.

6.

Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer.

Aminkeng F, Ross CJD, Rassekh SR, Rieder MJ, Bhavsar AP, Sanatani S, Bernstein D, Hayden MR, Amstutz U, Carleton BC.

Br J Clin Pharmacol. 2017 May;83(5):1143-1145. doi: 10.1111/bcp.13218. Epub 2017 Mar 19. No abstract available.

7.

Exome Sequencing and the Management of Neurometabolic Disorders.

Tarailo-Graovac M, Shyr C, Ross CJ, Horvath GA, Salvarinova R, Ye XC, Zhang LH, Bhavsar AP, Lee JJ, Drögemöller BI, Abdelsayed M, Alfadhel M, Armstrong L, Baumgartner MR, Burda P, Connolly MB, Cameron J, Demos M, Dewan T, Dionne J, Evans AM, Friedman JM, Garber I, Lewis S, Ling J, Mandal R, Mattman A, McKinnon M, Michoulas A, Metzger D, Ogunbayo OA, Rakic B, Rozmus J, Ruben P, Sayson B, Santra S, Schultz KR, Selby K, Shekel P, Sirrs S, Skrypnyk C, Superti-Furga A, Turvey SE, Van Allen MI, Wishart D, Wu J, Wu J, Zafeiriou D, Kluijtmans L, Wevers RA, Eydoux P, Lehman AM, Vallance H, Stockler-Ipsiroglu S, Sinclair G, Wasserman WW, van Karnebeek CD.

N Engl J Med. 2016 Jun 9;374(23):2246-55. doi: 10.1056/NEJMoa1515792. Epub 2016 May 25.

8.

Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.

Aminkeng F, Ross CJ, Rassekh SR, Hwang S, Rieder MJ, Bhavsar AP, Smith A, Sanatani S, Gelmon KA, Bernstein D, Hayden MR, Amstutz U, Carleton BC; CPNDS Clinical Practice Recommendations Group.

Br J Clin Pharmacol. 2016 Sep;82(3):683-95. doi: 10.1111/bcp.13008. Epub 2016 Jun 30. Review.

9.

Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers.

Lee JW, Pussegoda K, Rassekh SR, Monzon JG, Liu G, Hwang S, Bhavsar AP, Pritchard S, Ross CJ, Amstutz U, Carleton BC; CPNDS Clinical Recommendations Group.

Ther Drug Monit. 2016 Aug;38(4):423-31. doi: 10.1097/FTD.0000000000000298. Review.

10.

A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.

Aminkeng F, Bhavsar AP, Visscher H, Rassekh SR, Li Y, Lee JW, Brunham LR, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Amstutz U, Rieder MJ, Bernstein D, Carleton BC, Hayden MR, Ross CJ; Canadian Pharmacogenomics Network for Drug Safety Consortium.

Nat Genet. 2015 Sep;47(9):1079-84. doi: 10.1038/ng.3374. Epub 2015 Aug 3.

11.

Genetic markers of cisplatin-induced hearing loss in children.

Carleton BC, Ross CJ, Pussegoda K, Bhavsar AP, Visscher H, Lee JW, Brooks B, Rassekh SR, Dubé MP, Hayden MR.

Clin Pharmacol Ther. 2014 Sep;96(3):296-8. doi: 10.1038/clpt.2014.92.

PMID:
25141953
12.

Response to "evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity".

Carleton BC, Ross CJ, Bhavsar AP, Lee JW, Visscher H, Rassekh SR, Hayden MR.

Clin Pharmacol Ther. 2014 Aug;96(2):158. doi: 10.1038/clpt.2014.90. Epub 2014 Apr 22. No abstract available.

PMID:
24755913
13.

The emerging era of pharmacogenomics: current successes, future potential, and challenges.

Lee JW, Aminkeng F, Bhavsar AP, Shaw K, Carleton BC, Hayden MR, Ross CJ.

Clin Genet. 2014 Jul;86(1):21-8. doi: 10.1111/cge.12392. Epub 2014 May 9. Review.

14.

Mitochondrial carbonic anhydrase VA deficiency resulting from CA5A alterations presents with hyperammonemia in early childhood.

van Karnebeek CD, Sly WS, Ross CJ, Salvarinova R, Yaplito-Lee J, Santra S, Shyr C, Horvath GA, Eydoux P, Lehman AM, Bernard V, Newlove T, Ukpeh H, Chakrapani A, Preece MA, Ball S, Pitt J, Vallance HD, Coulter-Mackie M, Nguyen H, Zhang LH, Bhavsar AP, Sinclair G, Waheed A, Wasserman WW, Stockler-Ipsiroglu S.

Am J Hum Genet. 2014 Mar 6;94(3):453-61. doi: 10.1016/j.ajhg.2014.01.006. Epub 2014 Feb 13.

15.

Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity.

Carleton BC, Ross CJ, Bhavsar AP, Amstutz U, Pussegoda K, Visscher H, Lee JW, Brooks B, Rassekh SR, Dubé MP, Hayden MR.

Clin Pharmacol Ther. 2014 Mar;95(3):253. doi: 10.1038/clpt.2013.219. Epub 2013 Nov 5. No abstract available.

PMID:
24193170
16.

The Salmonella type III effector SspH2 specifically exploits the NLR co-chaperone activity of SGT1 to subvert immunity.

Bhavsar AP, Brown NF, Stoepel J, Wiermer M, Martin DD, Hsu KJ, Imami K, Ross CJ, Hayden MR, Foster LJ, Li X, Hieter P, Finlay BB.

PLoS Pathog. 2013;9(7):e1003518. doi: 10.1371/journal.ppat.1003518. Epub 2013 Jul 25.

17.

Global impact of Salmonella pathogenicity island 2-secreted effectors on the host phosphoproteome.

Imami K, Bhavsar AP, Yu H, Brown NF, Rogers LD, Finlay BB, Foster LJ.

Mol Cell Proteomics. 2013 Jun;12(6):1632-43. doi: 10.1074/mcp.M112.026161. Epub 2013 Mar 3.

18.

The pathogenic Escherichia coli type III secreted protease NleC degrades the host acetyltransferase p300.

Shames SR, Bhavsar AP, Croxen MA, Law RJ, Mak SH, Deng W, Li Y, Bidshari R, de Hoog CL, Foster LJ, Finlay BB.

Cell Microbiol. 2011 Oct;13(10):1542-57. doi: 10.1111/j.1462-5822.2011.01640.x. Epub 2011 Aug 4.

PMID:
21812888
19.

Quantitative mass spectrometry catalogues Salmonella pathogenicity island-2 effectors and identifies their cognate host binding partners.

Auweter SD, Bhavsar AP, de Hoog CL, Li Y, Chan YA, van der Heijden J, Lowden MJ, Coombes BK, Rogers LD, Stoynov N, Foster LJ, Finlay BB.

J Biol Chem. 2011 Jul 8;286(27):24023-35. doi: 10.1074/jbc.M111.224600. Epub 2011 May 12.

20.

Proteomics as a probe of microbial pathogenesis and its molecular boundaries.

Bhavsar AP, Auweter SD, Finlay BB.

Future Microbiol. 2010 Feb;5(2):253-65. doi: 10.2217/fmb.09.114. Review.

PMID:
20143948
21.

Probing teichoic acid genetics with bioactive molecules reveals new interactions among diverse processes in bacterial cell wall biogenesis.

D'Elia MA, Millar KE, Bhavsar AP, Tomljenovic AM, Hutter B, Schaab C, Moreno-Hagelsieb G, Brown ED.

Chem Biol. 2009 May 29;16(5):548-56. doi: 10.1016/j.chembiol.2009.04.009.

22.

Host factor reveals the intrinsic enzymatic activity of a bacterial effector.

Auweter SD, Bhavsar AP, Finlay BB.

Future Microbiol. 2008 Dec;3(6):617-20. doi: 10.2217/17460913.3.6.617. Review. No abstract available.

PMID:
19072178
23.

Manipulation of host-cell pathways by bacterial pathogens.

Bhavsar AP, Guttman JA, Finlay BB.

Nature. 2007 Oct 18;449(7164):827-34. Review.

PMID:
17943119
24.

The Amino terminus of Bacillus subtilis TagB possesses separable localization and functional properties.

Bhavsar AP, D'Elia MA, Sahakian TD, Brown ED.

J Bacteriol. 2007 Oct;189(19):6816-23. Epub 2007 Jul 27.

25.

The worm turns for antimicrobial discovery.

Bhavsar AP, Brown ED.

Nat Biotechnol. 2006 Sep;24(9):1098-100. No abstract available.

PMID:
16964218
26.

Cell wall assembly in Bacillus subtilis: how spirals and spaces challenge paradigms.

Bhavsar AP, Brown ED.

Mol Microbiol. 2006 Jun;60(5):1077-90. Review.

28.

Two conserved histidine residues are critical to the function of the TagF-like family of enzymes.

Schertzer JW, Bhavsar AP, Brown ED.

J Biol Chem. 2005 Nov 4;280(44):36683-90. Epub 2005 Sep 1.

29.

Teichoic acid is an essential polymer in Bacillus subtilis that is functionally distinct from teichuronic acid.

Bhavsar AP, Erdman LK, Schertzer JW, Brown ED.

J Bacteriol. 2004 Dec;186(23):7865-73.

31.

Development and characterization of a xylose-dependent system for expression of cloned genes in Bacillus subtilis: conditional complementation of a teichoic acid mutant.

Bhavsar AP, Zhao X, Brown ED.

Appl Environ Microbiol. 2001 Jan;67(1):403-10. Erratum in: Appl Environ Microbiol 2001 Nov;67(11):5349.

Supplemental Content

Loading ...
Support Center